Top

Published in:

01-12-2014 | Review

The impact of hepatitis B virus x protein and microRNAs in hepatocellular carcinoma: a comprehensive analysis

Authors: Li Lin, Xiaomao Yin, Xiumei Hu, Qian Wang, Lei Zheng

Published in: Tumor Biology | Issue 12/2014

Abstract

microRNAs (miRNAs) are evolutionarily conserved small non-coding RNAs, approximately 22 nucleotides (nts) in length, widely found in animals, plants, and viruses. Mature miRNAs control gene expression at a post-transcriptional level through blocking protein translation or inducing mRNA degradation. Many recent studies have shown that hepatitis B virus x protein (HBx), a viral protein with a crucial role in hepatogenesis, is associated with the regulation of miRNAs. This interaction impacts fundamental tumor processes, such as cell proliferation, differentiation, and apoptosis. In this review, we summarized the recent literature on the roles of HBx-regulated miRNAs in the pathogenesis of hepatocellular carcinoma.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

Kew MC. Epidemiology of chronic hepatitis b virus infection, hepatocellular carcinoma, and hepatitis b virus-induced hepatocellular carcinoma. Pathol Biol. 2010;58:273–7.PubMed

Zhang X, Zhang H, Ye L. Effects of hepatitis b virus x protein on the development of liver cancer. J Lab Clin Med. 2006;147:58–66.PubMed

Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the x transcript of hepatitis b virus in patients negative for hepatitis b surface antigen with hepatocellular carcinoma. Hepatology (Baltimore, Md). 1995;21:313–21.

Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–54.

Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science (New York, NY). 2001;294:862–4.

Ambros V, Lee RC, Lavanway A, Williams PT, Jewell D. MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr Biol: CB. 2003;13:807–18.PubMed

Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004.PubMedPubMedCentral

Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science (New York, NY). 2005;309:1519–24.

10.

He L, Hannon GJ. MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–31.

11.

Cuperus JT, Fahlgren N, Carrington JC. Evolution and functional diversification of miRNA genes. Plant Cell. 2011;23:431–42.PubMedPubMedCentral

12.

Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' utr as in the 3' utr. Proc Natl Acad Sci U S A. 2007;104:9667–72.PubMedPubMedCentral

13.

Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. Mirbase: MicroRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006;34:D140–4.PubMed

14.

Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25:2537–45.PubMed

15.

Jiang R, Deng L, Zhao L, Li X, Zhang F, Xia Y, et al. Mir-22 promotes hbv-related hepatocellular carcinoma development in males. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17:5593–603.

16.

Dang Y, Luo D, Rong M, Chen G. Underexpression of mir-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-met. PLoS One. 2013;8:e61054.PubMedPubMedCentral

17.

Wu XJ, Li Y, Liu D, Zhao LD, Bai B, Xue MH. Mir-27a as an oncogenic microRNA of hepatitis b virus- related hepatocellular carcinoma. Asian Pac J Cancer Prev: APJCP. 2013;14:885–9.PubMed

18.

Fan CG, Wang CM, Tian C, Wang Y, Li L, Sun WS, et al. Mir-122 inhibits viral replication and cell proliferation in hepatitis b virus-related hepatocellular carcinoma and targets ndrg3. Oncol Rep. 2011;26:1281–6.PubMed

19.

Yang P, Li QJ, Feng Y, Zhang Y, Markowitz GJ, Ning S, et al. Tgf-beta-mir-34a-ccl22 signaling-induced treg cell recruitment promotes venous metastases of hbv-positive hepatocellular carcinoma. Cancer Cell. 2012;22:291–303.PubMedPubMedCentral

20.

Klein R, Schroder CH, Zentgraf H. Expression of the x protein of hepatitis b virus in insect cells using recombinant baculoviruses. Virus Genes. 1991;5:157–74.PubMed

21.

Schek N, Bartenschlager R, Kuhn C, Schaller H. Phosphorylation and rapid turnover of hepatitis b virus x-protein expressed in hepg2 cells from a recombinant vaccinia virus. Oncogene. 1991;6:1735–44.PubMed

22.

Spandau DF, Wang HG, Fraser MJ, Lee CH. A functional hepatitis b virus x protein produced in insect cells. Virology. 1991;185:938–41.PubMed

23.

Gong P, Zhang X, Zhang J, Zhang J, Luo H, Wang Z. Hepatitis b virus x protein in the proliferation of hepatocellular carcinoma cells. Front Biosci (Landmark edition). 2013;18:1256–65.

24.

Cha MY, Kim CM, Park YM, Ryu WS. Hepatitis b virus x protein is essential for the activation of wnt/beta-catenin signaling in hepatoma cells. Hepatology (Baltimore, Md). 2004;39:1683–93.

25.

Yun C, Cho H, Kim SJ, Lee JH, Park SY, Chan GK, et al. Mitotic aberration coupled with centrosome amplification is induced by hepatitis b virus x oncoprotein via the ras-mitogen-activated protein/extracellular signal-regulated kinase-mitogen-activated protein pathway. Mol Cancer Res: MCR. 2004;2:159–69.PubMed

26.

Lu JW, Yang WY, Tsai SM, Lin YM, Chang PH, Chen JR, et al. Liver-specific expressions of hbx and src in the p53 mutant trigger hepatocarcinogenesis in zebrafish. PLoS One. 2013;8:e76951.PubMedPubMedCentral

27.

Kordestani R, Mirshafiee H, Hosseini SM, Sharifi Z. Effect of hepatitis b virus x gene on the expression level of p53 gene using hep g2 cell line. Avicenna J Med Biotechnol. 2014;6:3–9.PubMedPubMedCentral

28.

Capovilla A, Carmona S, Arbuthnot P. Hepatitis b virus x-protein binds damaged DNA and sensitizes liver cells to ultraviolet irradiation. Biochem Biophys Res Commun. 1997;232:255–60.PubMed

29.

Gearhart TL, Bouchard MJ. The hepatitis b virus x protein modulates hepatocyte proliferation pathways to stimulate viral replication. J Virol. 2010;84:2675–86.PubMedPubMedCentral

30.

Li CH, Xu F, Chow S, Feng L, Yin D, Ng TB, et al. Hepatitis b virus x protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microrna-21 expression. Eur J Cancer (Oxford, England: 1990). 2014.

31.

Tong A, Gou L, Lau QC, Chen B, Zhao X, Li J, et al. Proteomic profiling identifies aberrant epigenetic modifications induced by hepatitis b virus x protein. J Proteome Res. 2009;8:1037–46.PubMed

32.

Girault I, Tozlu S, Lidereau R, Bieche I. Expression analysis of DNA methyltransferases 1, 3a, and 3b in sporadic breast carcinomas. Clin Cancer Res: Off J Am Assoc Cancer Res. 2003;9:4415–22.

33.

Wei X, Xiang T, Ren G, Tan C, Liu R, Xu X, et al. Mir-101 is down-regulated by the hepatitis b virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3a. Cell Signal. 2013;25:439–46.PubMed

34.

Huang J, Wang Y, Guo Y, Sun S. Down-regulated microrna-152 induces aberrant DNA methylation in hepatitis b virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology (Baltimore, Md). 2010;52:60–70.

35.

Zhang T, Zhang J, Cui M, Liu F, You X, Du Y, et al. Hepatitis b virus x protein inhibits tumor suppressor mir-205 through inducing hypermethylation of mir-205 promoter to enhance carcinogenesis. Neoplasia (New York, NY). 2013;15:1282–91.

36.

Wei X, Tan C, Tang C, Ren G, Xiang T, Qiu Z, et al. Epigenetic repression of mir-132 expression by the hepatitis b virus x protein in hepatitis b virus-related hepatocellular carcinoma. Cell Signal. 2013;25:1037–43.PubMed

37.

Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle (Georgetown, Tex). 2007;6:2127–32.

38.

Wang CM, Wang Y, Fan CG, Xu FF, Sun WS, Liu YG, et al. Mir-29c targets tnfaip3, inhibits cell proliferation and induces apoptosis in hepatitis b virus-related hepatocellular carcinoma. Biochem Biophys Res Commun. 2011;411:586–92.PubMed

39.

Zhu XM, Wu LJ, Xu J, Yang R, Wu FS. Let-7c microRNA expression and clinical significance in hepatocellular carcinoma. J Int Med Res. 2011;39:2323–9.PubMed

40.

Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The microrna let-7a modulates interleukin-6-dependent stat-3 survival signaling in malignant human cholangiocytes. J Biol Chem. 2007;282:8256–64.PubMed

41.

Cao Q, Li YY, He WF, Zhang ZZ, Zhou Q, Liu X, et al. Interplay between microRNAs and the stat3 signaling pathway in human cancers. Physiol Genomics. 2013;45:1206–14.PubMed

42.

Wang Y, Lu Y, Toh ST, Sung WK, Tan P, Chow P, et al. Lethal-7 is down-regulated by the hepatitis b virus x protein and targets signal transducer and activator of transcription 3. J Hepatol. 2010;53:57–66.PubMed

43.

Wu G, Yu F, Xiao Z, Xu K, Xu J, Tang W, et al. Hepatitis b virus x protein downregulates expression of the mir-16 family in malignant hepatocytes in vitro. Br J Cancer. 2011;105:146–53.PubMedPubMedCentral

44.

Wu CS, Yen CJ, Chou RH, Chen JN, Huang WC, Wu CY, et al. Downregulation of microRNA-15b by hepatitis b virus x enhances hepatocellular carcinoma proliferation via fucosyltransferase 2-induced globo h expression. Int J Cancer J Int Cancer. 2014;134:1638–47.

45.

Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT. Identification of deregulated miRNAs and their targets in hepatitis b virus-associated hepatocellular carcinoma. World J Gastroenterol: WJG. 2012;18:5442–53.PubMedPubMedCentral

46.

Yuan K, Lian Z, Sun B, Clayton MM, Ng IO, Feitelson MA. Role of mir-148a in hepatitis b associated hepatocellular carcinoma. PLoS One. 2012;7:e35331.PubMedPubMedCentral

47.

Gailhouste L, Gomez-Santos L, Hagiwara K, Hatada I, Kitagawa N, Kawaharada K, et al. Mir-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells. Hepatology (Baltimore, Md). 2013;58:1153–65.

48.

Xu X, Fan Z, Kang L, Han J, Jiang C, Zheng X, et al. Hepatitis b virus x protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest. 2013;123:630–45.PubMedPubMedCentral

49.

Zhang X, Liu S, Hu T, Liu S, He Y, Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa b enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology (Baltimore, Md). 2009;50:490–9.

50.

Kong G, Zhang J, Zhang S, Shan C, Ye L, Zhang X. Upregulated microrna-29a by hepatitis b virus x protein enhances hepatoma cell migration by targeting pten in cell culture model. PLoS One. 2011;6:e19518.PubMedPubMedCentral

51.

Zhao J, Wang W, Huang Y, Wu J, Chen M, Cui P, et al. Hbx elevates oncoprotein aeg-1 expression to promote cell migration by downregulating mir-375 and mir-136 in malignant hepatocytes. DNA Cell Biol. 2014.

52.

Cui M, Xiao Z, Sun B, Wang Y, Zheng M, Ye L, et al. Involvement of cholesterol in hepatitis b virus x protein-induced abnormal lipid metabolism of hepatoma cells via up-regulating mir-205-targeted acsl4. Biochem Biophys Res Commun. 2014;445:651–5.PubMed

53.

Cui M, Wang Y, Sun B, Xiao Z, Ye L, Zhang X. Mir-205 modulates abnormal lipid metabolism of hepatoma cells via targeting acyl-coa synthetase long-chain family member 1 (acsl1) mRNA. Biochem Biophys Res Commun. 2014;444:270–5.PubMed

54.

Liu F, You X, Chi X, Wang T, Ye L, Niu J, et al. Hepatitis b virus x protein mutant hbxdelta127 promotes proliferation of hepatoma cells through up-regulating mir-215 targeting ptprt. Biochem Biophys Res Commun. 2014;444:128–34.PubMed

55.

Tu H, Bonura C, Giannini C, Mouly H, Soussan P, Kew M, et al. Biological impact of natural cooh-terminal deletions of hepatitis b virus x protein in hepatocellular carcinoma tissues. Cancer Res. 2001;61:7803–10.PubMed

Title: The impact of hepatitis B virus x protein and microRNAs in hepatocellular carcinoma: a comprehensive analysis
Authors: Li Lin
Xiaomao Yin
Xiumei Hu
Qian Wang
Lei Zheng
Publication date: 01-12-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2658-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2014

Nucleotidyl transferase TUT1 inhibits lipogenesis in osteosarcoma cells through regulation of microRNA-24 and microRNA-29a

MiR-212 exerts suppressive effect on SKOV3 ovarian cancer cells through targeting HBEGF

IL-27 −964A>G polymorphism and the risk of breast cancer: a case–control study

A novel NF-κB/MMP-3 signal pathway involves in the aggressivity of glioma promoted by Bmi-1

MiR99a modulates MMP7 and MMP13 to regulate invasiveness of Kaposi’s sarcoma

11C-choline PET/CT tumor recurrence detection and survival prediction in post-treatment patients with high-grade gliomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer